@article {4502,
	title = {Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.},
	journal = {Transplant infectious disease : an official journal of the Transplantation Society// Transpl Infect Dis},
	volume = {16},
	year = {2014},
	month = {2014//},
	pages = {1003 - 6},
	address = {Denmark},
	abstract = {Transmission of hepatitis C virus (HCV) to recipients of hematopoietic stem cell transplant (HSCT) occurs frequently from HCV viremic donors and causes complications. Here, we report the outcomes of 3 cases from our 265 allogeneic HSCTs, whose donors had HCV infections. Successful prevention of HCV transmission was noted in 1 recipient by pretreatment of the donor with peginterferon/ribavirin to undetectable levels of HCV viremia before stem cell harvest. This case stressed the important role of effective antiviral therapy and HCV RNA seronegativity before cell harvest for prevention of HCV transmission in HSCT. Copyright {\textcopyright} 2014 John Wiley \& Sons A/S. Published by John Wiley \& Sons Ltd.},
	keywords = {*Hematopoietic Stem Cell Transplantation/ae [Adverse Effects], *Hepatitis C/tm [Transmission], *Viremia, Adult, Antiviral Agents/ad [Administration \& Dosage], Antiviral Agents/tu [Therapeutic Use], Drug Therapy, Combination, Female, Hepacivirus/ip [Isolation \& Purification], Hepatitis C/dt [Drug Therapy], Hepatitis C/vi [Virology], Humans, Interferon-alpha/ad [Administration \& Dosage], Interferon-alpha/tu [Therapeutic Use], Male, Polyethylene Glycols/ad [Administration \& Dosage], Polyethylene Glycols/tu [Therapeutic Use], Recombinant Proteins/ad [Administration \& Dosage], Recombinant Proteins/tu [Therapeutic Use], Ribavirin/ad [Administration \& Dosage], Ribavirin/tu [Therapeutic Use], RNA, Viral/bl [Blood], Tissue Donors, Viral Load},
	isbn = {1399-3062},
	author = {Hsiao, H-H and Liu, Y-C and Wang, H-C and Wu, C-H and Cho, S-F and Hsu, J-F and Tsai, H-J and Hsiao, S Y and Chang, C-S and Lin, S-F and Liu, T-C and Chuang, W-L and Yu, M-L}
}
